Liver transplant study for liver cancer patients
Part of Cancer, Digestive system clinical trials.
This study looks at two blood markers (AFP and PIVKA-II) to see if they can help predict outcomes for people getting a liver transplant for liver cancer. It aims to find better ways to guide care after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (HCC) through an imaging scan like a CT or MRI, or through a needle biopsy.
- You are getting a liver transplant from a deceased donor for the first time.
- You have not had a split liver transplant or another organ transplant at the same time.
- You do not have a blood clot in the large vein of your liver (called portal vein tumor thrombosis) or other major blood vessel invasion.
- You are not taking the blood thinner warfarin at the time the study measures your blood markers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people having liver cancer surgery. It will look at certain fats in your blood to see if they can help doctors understand and track liver cancer better.
This trial studies how a whole-body PET/CT scan using a “tracer” called 18F-FDG can help decide which people with liver cancer (HCC) may benefit from a liver transplant. It may help the transplant team better sort out who is likely to do well after transplant.
This study uses a blood test (looking at sugars in the blood) to help predict whether liver cancer will come back after a liver transplant. It may help doctors monitor you more accurately and earlier if cancer returns.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.